Klertis

Sunitinib, the active ingredient in Klertis, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats advanced renal cell carcinoma, gastrointestinal stromal tumor and pancreatic neuroendocrine tumor in adult patients. GNH USA supplies Klertis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Sunitinib is indicated for malignancies that depend on receptor tyrosine kinase signaling.

Renal cell carcinoma: improves progression‑free survival and disease control in patients with advanced or metastatic renal cell carcinoma. Gastrointestinal stromal tumor (GIST): provides disease control and tumor shrinkage in patients with unresectable or metastatic GIST after prior treatment. Pancreatic neuroendocrine tumor: extends overall survival and delays disease progression in patients with advanced pancreatic neuroendocrine tumors.

Sunitinib may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require fluid replacement. - Nausea: feeling of sickness often accompanied by vomiting. - Hand‑foot syndrome: redness, swelling or pain on palms and soles.

Serious or Rare Side Effects: - Hypertension: significant increase in blood pressure that may need medication. - Cardiac dysfunction: reduced left‑ventricular ejection fraction or heart failure. - Severe liver injury: marked elevation of liver enzymes or hepatitis.

Before initiating therapy with Sunitinib, several safety considerations should be reviewed. - Baseline cardiac assessment: evaluate heart function with echocardiogram or MUGA scan. - Blood pressure monitoring: check and control hypertension regularly. - Liver function tests: perform baseline and periodic hepatic enzyme assessments. - Hematologic monitoring: monitor complete blood count for neutropenia or thrombocytopenia. - Pregnancy and lactation: avoid use in pregnancy; discuss risks with a healthcare professional. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Sunitinib can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase sunitinib exposure and toxicity (e.g., ketoconazole, clarithromycin). - Strong CYP3A4 inducers: may reduce sunitinib levels and efficacy (e.g., rifampin, carbamazepine).

Moderate Interactions (Monitor Closely): - Anticoagulants: increased bleeding risk; monitor INR or clinical signs. - Antihypertensives: additive blood pressure effects; adjust dosing as needed. - CYP2C8 substrates: potential altered metabolism; observe for adverse effects.